Tag: Oncolytic virus

World-first clinical trial for oncolytic virus immunotherapy featured by The National

Last night, CBC TV’s The National introduced its audience to a novel clinical trial currently underway in Canada. The trial has been partially enabled by support from BioCanRx to manufacture the engineered viruses being given to the study’s participants.     The clinical trial is testing a new investigational therapy called oncolytic virus immunotherapy, which… Read more »

First cancer-killing virus therapy approved by the FDA

On Oct. 27, 2015, the U.S. FDA gave its first approval for the use of a cancer-killing virus therapy, or oncolytic virus. Specifically, the FDA approved Amgen’s Imlygic, which is generically known as T-VEC, for the treatment of melanoma lesions in the skin and lymph nodes.   “This approval is a huge milestone for the… Read more »

Cancer patients treated in world-first clinical trial of Canadian viral therapy

Clinical Trials, Media release   Canadian researchers have launched the world’s first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and… Read more »

Pancreatic cancer loses viral defences when talking with supporting cells

Media release   Ottawa researchers have unlocked a way to make pancreatic cancer cells more vulnerable to cancer-killing viruses, known as oncolytic viruses. Outlined in a paper published today by Nature Medicine, the scientists have discovered how they can exploit the communication, or cross-talk, between pancreatic cancer and a specific cell type that supports the… Read more »